Posts

Flagship commits £100 million to launch AI biotech lab in London

Flagship Pioneering announced on November 16, 2026, that it will establish the Flagship Origination Lab, U.K., in London—its first dedicated company-creation unit outside the United States. The firm committed an initial £100 million (about US$132 million) to launch the lab. It aims to attract a further £500 million through partnerships; that additional funding is an aspiration, not yet secured. The lab will develop, test, fund, and build AI-native companies spanning human and planetary health and other areas of science. Flagship says AI will be used throughout the company-building process. Flagship expects to recruit an initial team of about 50 scientist-entrepreneurs and operators. Reuters reported the firm hopes to build eight to 10 UK-based biotechs over the next few years. Unlike a conventional venture fund investing mainly in existing startups, Flagship says it plans to create new companies, working with universities, corporations, and other partners. Sources: Venture ...

Sofinnova closes €725M fund for late-stage life sciences companies

CG Oncology reports strong Phase 3 bladder cancer results

J&J to acquire Ollin Biosciences for up to $3.33 billion

Helus Pharma shares fall despite positive Phase 3 depression results

Roche enters the SERD market with FDA approval for advanced breast cancer

Biogen backs TRIM21-based protein degraders in potential $411 million TRIMTECH deal

Petosemtamab’s first-line HNSCC results could reshape treatment sequencing

FDA clears MiniMed Fit, a new seven-day tubeless insulin pump

OpenAI expands ChatGPT for Healthcare with AI agents and Elation Health plugin

AstraZeneca reportedly cuts about 600 U.S. commercial roles

Lilly to acquire Calytrix Bio for up to $1.5 billion

FDA blocks ivonescimab’s near-term US launch over survival-data concerns